Danaparoid (Orgaran)

General Information

  • Discontinued in US in 2002

Indications

  • Heparin-Induced Thrombocytopenia (HIT) (see Heparin-Induced Thrombocytopenia, [[Heparin-Induced Thrombocytopenia]])
    • One of the recommended agents, per Chest 2012 guidelines [MEDLINE]: however, it is not FDA approved for HIT

Pharmacology

  • Factor Xa Inhibitor (see Factor Xa Inhibitors, [[Factor Xa Inhibitors]])
  • Half-Life: 25 hrs
  • Metabolism: renal

Administration

  • IV
  • SQ

Adverse Effects

Hemorrhagic Adverse Effects

Other Adverse Effects

  • xxx
  • xxx

References

  • xxxx